On June 25, "Vaccines" published the "Evaluation of the Immunogenicity and Safety of the New Crown Inactivated Vaccine in Elderly People with Hypertension and Diabetes" published by Sinopharm China Biotech.

On June 25, "Vaccines" published the "Evaluation of immunogenicity and safety of the new coronavirus inactivated vaccine in the elderly with hypertension and diabetes " published by Sinopharm China Biotech. safety of vero cell-derived inactivated COVID-19 vaccine in older patients with hypertension and diabetes mellitus”). The results of the study showed that after receiving two doses of the China Biotech COVID-19 vaccine, the positive conversion rate of new coronavirus neutralizing antibodies in all subjects was 100%. The antibody positive conversion rates in the hypertension group, diabetes group, and combined disease group were all non-inferior. Healthy control group; no serious adverse reactions related to vaccination were reported.

The research was jointly sponsored by Sinopharm China Biotechnology and its affiliated Beijing Institute of Biological Products and Hunan Provincial Center for Disease Control and Prevention , Guizhou Provincial Center for Disease Control and Prevention , Fujian Provincial Center for Disease Control and Prevention , Peking University and many others It is completed through cooperation between institutions and units. Researcher Yang Xiaoming, chief scientist of the "863 Plan" vaccine project of the Ministry of Science and Technology and chairman of China Biotechnology, and Director Li Liming, director of the Strategic Research Center for Public Health and Major Epidemic Prevention and Control at Peking University and professor at the School of Public Health, jointly serve as the corresponding authors of ., China Biotechnology Zhang Yuntao, director of the Clinical Medicine Center, Chen Haiping, manager of the Medical Affairs Department of the Marketing Center, and Professor Lu Jun of the School of Public Health of Peking University are the co-first authors.

In this study, 1440 subjects aged ≥60 years were divided into 4 research groups according to their health status: hypertension group, diabetes group, combined disease group (suffering from both hypertension and diabetes) and healthy control group. All subjects were vaccinated with two doses of the new coronavirus inactivated vaccine produced by China National Biotechnology Beijing Institute of Biological Products, with an interval of 21 days between the two doses. Before the first dose of vaccination and 28 days after the second dose of vaccination, blood was collected to detect the new coronavirus neutralizing antibody titer. blood pressure monitors were distributed to the hypertension group and the combined disease group, and blood sugar was distributed to the diabetes group and the combined disease group. Instrument is used to monitor fluctuations in blood pressure and blood sugar levels after vaccination. The immunogenicity results of

showed that after two doses of vaccination, the positive conversion rate of new coronavirus neutralizing antibodies in all subjects was 100%. The antibody positive conversion rates in the hypertension group, diabetes group, and combined disease group were all non-inferior to healthy controls. Group. The post-immune antibody GMT of the new coronavirus in the hypertension group, diabetes group, combined disease group and healthy control group were 73.41 (95% CI 67.24 ~ 80.14), 69.93 (95% CI 63.59 ~ 76.89), and 73.84 (95% CI 66.70 ~ 81.75) respectively. ; Control group. After stratifying the subjects according to age (60-69 years old and ≥70 years old) and gender, the antibody positive conversion rate and post-immunization GMT results were similar to the above results.

▲The picture above shows the GMT levels of COVID-19 neutralizing antibodies in the four study groups of subjects over 60 years old, stratified by age and gender. There was no statistically significant difference between the groups (P 0.05).

The safety results show that high The incidence rates of total adverse events in the blood pressure group, diabetes group, combined disease group and healthy control group after two doses of vaccine were 11.93%, 14.29%, 12.50% and 9.38% respectively, with no statistically significant difference between the groups (P= 0.185). The reported adverse events were mainly mild in severity, and no serious adverse events related to vaccination were reported.

The above research results confirm that the new coronavirus inactivated vaccine has good immunogenicity and safety in people aged 60 and above with hypertension and diabetes. After being vaccinated, subjects with hypertension and diabetes There were no significant fluctuations in his blood pressure and blood sugar levels. Provide strong data support to encourage the elderly with underlying diseases (such as hypertension, diabetes) to complete the full course of COVID-19 vaccine in a timely manner, which will help improve the coverage of COVID-19 vaccination among the elderly in China and establish an immune barrier for vulnerable elderly groups. .

Source: China Bio